About Epizyme (NASDAQ:EPZM)
Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops novel epigenetic medicines for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial in elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function,; and Phase Ib/II clinical trial for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer, as well as Phase II clinical trial in adult patients with ovarian cancer. The company is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias; and PRMT5 inhibitor that is in Phase I clinical trial for patients with solid tumors and NHL. It has collaboration agreements with Celgene Corporation, Genentech Inc., and Glaxo Group Limited, as well as with Roche Molecular Systems, Inc., Eisai Co. Ltd., and Lymphoma Study Association. Epizyme, Inc. was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EPZM
CUSIPN/A
Phone617-229-5872
Debt
Debt-to-Equity RatioN/A
Current Ratio11.59%
Quick Ratio11.59%
Price-To-Earnings
Trailing P/E Ratio-6.17
Forward P/E Ratio-5.65
P/E GrowthN/A
Sales & Book Value
Annual Sales$10 million
Price / Sales93.45
Cash FlowN/A
Price / CashN/A
Book Value$3.40 per share
Price / Book3.96
Profitability
EPS (Most Recent Fiscal Year)($2.18)
Net Income$-134,300,000.00
Net MarginsN/A
Return on Equity-64.88%
Return on Assets-51.70%
Miscellaneous
Employees131
Outstanding Shares69,480,000
Epizyme (NASDAQ:EPZM) Frequently Asked Questions
What is Epizyme's stock symbol?
Epizyme trades on the NASDAQ under the ticker symbol "EPZM."
How were Epizyme's earnings last quarter?
Epizyme (NASDAQ:EPZM) released its quarterly earnings data on Tuesday, March, 13th. The biopharmaceutical company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.05. The firm's quarterly revenue was down 100.0% compared to the same quarter last year. View Epizyme's Earnings History.
When is Epizyme's next earnings date?
What price target have analysts set for EPZM?
12 brokers have issued twelve-month price objectives for Epizyme's stock. Their predictions range from $16.00 to $26.00. On average, they anticipate Epizyme's share price to reach $22.5455 in the next year. View Analyst Ratings for Epizyme.
What are Wall Street analysts saying about Epizyme stock?
Here are some recent quotes from research analysts about Epizyme stock:
- 1. According to Zacks Investment Research, "Epizyme reported narrower than expected loss in the fourth quarter of 2017. Epizyme's efforts on developing its lead candidate, tazemetostat, for a number of hematological malignancies and genetically defined solid tumors are impressive. During the fourth quarter of 2017, the company had a productive interaction with the FDA to design the registration strategy for tazemetostat for epithelioid sarcomaand follicular lymphoma (FL) and identified a path to submit for accelerated approval for both the indications. The company plans to file a first new drug application of tazemetostat for epithelioid sarcoma in fourth quarter of 2018 and second NDA for FL in 2019. A potential approval for the candidate will be a significant boost for the company. So far this year, Epizyme’s share price has also outperformed the industry. However, the company is highly dependent on its collaboration partners for top-line growth with no approved product." (3/16/2018)
- 2. Cann analysts commented, "Epizyme presented two posters at the American Society of Hematology Meeting on December 10-11, 2017. These included a biomarker study in non-Hodgkin’s lymphoma (NHL) and preliminary response data from the diffuse large B cell lymphoma (DLBCL) cohort from the ongoing phase II study of tazemetostat in NHL. The data presented is very supportive of our outlook." (12/12/2017)
Who are some of Epizyme's key competitors?
Some companies that are related to Epizyme include Taro Pharmaceutical Industries (TARO), Loxo Oncology (LOXO), FibroGen (FGEN), GW Pharmaceuticals (GWPH), Advanced Accelerator Application (AAAP), Ligand Pharmaceuticals (LGND), Blueprint Medicines (BPMC), Array BioPharma (ARRY), Tesaro (TSRO), Emergent BioSolutions (EBS), Ultragenyx Pharmaceutical (RARE), Ironwood Pharmaceuticals (IRWD), Amicus Therapeutics (FOLD), Evotec A.G. (EVTCY) and Ascendis Pharma (ASND).
Who are Epizyme's key executives?
Epizyme's management team includes the folowing people:
- Mr. Robert B. Bazemore Jr., Pres, CEO, Sec. & Director (Age 50)
- Dr. H. Robert Horvitz Ph.D., M.D., Co-Founder and Chairman of the Scientific Advisory Board
- Dr. Yi Zhang Ph.D., Scientific Co-Founder and Member of The Scientific Advisory Board
- Mr. Matthew E. Ros, Chief Operating Officer (Age 51)
- Dr. Michael Boretti, VP of Bus. Devel.
Has Epizyme been receiving favorable news coverage?
News headlines about EPZM stock have been trending positive on Wednesday, according to Accern Sentiment. Accern identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Epizyme earned a coverage optimism score of 0.29 on Accern's scale. They also gave news coverage about the biopharmaceutical company an impact score of 45.18 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
How do I buy shares of Epizyme?
Shares of EPZM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Epizyme's stock price today?
One share of EPZM stock can currently be purchased for approximately $13.45.
How big of a company is Epizyme?
Epizyme has a market capitalization of $1.06 billion and generates $10 million in revenue each year. The biopharmaceutical company earns $-134,300,000.00 in net income (profit) each year or ($2.18) on an earnings per share basis. Epizyme employs 131 workers across the globe.
How can I contact Epizyme?
Epizyme's mailing address is 400 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-229-5872 or via email at [email protected]
MarketBeat Community Rating for Epizyme (EPZM)
MarketBeat's community ratings are surveys of what our community members think about Epizyme and other stocks. Vote "Outperform" if you believe EPZM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EPZM will underperform the S&P 500 over the long term. You may vote once every thirty days.
Epizyme (NASDAQ:EPZM) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
12 Wall Street analysts have issued ratings and price targets for Epizyme in the last 12 months. Their average twelve-month price target is $22.5455, suggesting that the stock has a possible upside of 67.62%. The high price target for EPZM is $26.00 and the low price target for EPZM is $16.00. There are currently 2 hold ratings and 10 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.83 | 2.92 | 2.91 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
2 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $22.5455 | $23.6364 | $22.8889 | $24.25 |
| Price Target Upside: | 67.62% upside | 24.08% upside | 39.14% upside | 25.97% upside |
Epizyme (NASDAQ:EPZM) Consensus Price Target History
Epizyme (NASDAQ:EPZM) Analyst Ratings History
Show:
(Data available from 4/25/2016 forward)
Epizyme (NASDAQ:EPZM) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Epizyme (NASDAQ EPZM) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 21.50%
Institutional Ownership Percentage: 85.77%
Epizyme (NASDAQ EPZM) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 2/5/2018 | Matthew Ros | COO | Sell | 72,264 | $16.63 | $1,201,750.32 | 74,867 |  |
| 10/24/2017 | Peter Tai-Ching Ho | Insider | Sell | 15,000 | $16.44 | $246,600.00 | 23,123 | |
| 9/25/2017 | Peter Tai-Ching Ho | Insider | Sell | 15,000 | $16.81 | $252,150.00 | 23,123 | |
| 9/18/2017 | David M Mott | Director | Buy | 200,000 | $15.25 | $3,050,000.00 | 6,000 | |
| 8/24/2017 | Peter Tai-Ching Ho | Insider | Sell | 15,000 | $15.68 | $235,200.00 | 22,228 | |
| 7/24/2017 | Peter Tai-Ching Ho | Insider | Sell | 15,000 | $13.44 | $201,600.00 | 22,228 | |
| 6/30/2017 | Andrew E Singer | CFO | Sell | 3,024 | $15.50 | $46,872.00 | 40,529 | |
| 6/26/2017 | Peter Tai-Ching Ho | Insider | Sell | 15,000 | $14.87 | $223,050.00 | 22,228 | |
| 6/6/2017 | Robert A Copeland | Insider | Sell | 2,500 | $13.45 | $33,625.00 | 34,038 | |
| 5/25/2017 | Peter Tai-Ching Ho | Insider | Sell | 15,000 | $16.11 | $241,650.00 | 22,228 | |
| 5/2/2017 | Robert A Copeland | Insider | Sell | 5,000 | $17.44 | $87,200.00 | 36,538 | |
| 4/4/2017 | Robert A Copeland | Insider | Sell | 5,000 | $16.36 | $81,800.00 | 33,538 | |
| 3/31/2017 | Andrew E Singer | CFO | Sell | 2,013 | $17.09 | $34,402.17 | 36,175 | |
| 1/9/2017 | Andrew E Singer | CFO | Sell | 1,013 | $12.04 | $12,196.52 | 33,506 | |
| 12/9/2016 | Andrew E Singer | CFO | Sell | 1,013 | $11.03 | $11,173.39 | 32,060 | |
| 11/9/2016 | Andrew E Singer | CFO | Sell | 1,013 | $10.40 | $10,535.20 | 30,613 | |
| 10/10/2016 | Andrew E Singer | CFO | Sell | 1,013 | $9.72 | $9,846.36 | 29,167 | |
| 9/9/2016 | Andrew E Singer | CFO | Sell | 1,013 | $7.55 | $7,648.15 | 27,721 | |
| 8/9/2016 | Andrew E Singer | CFO | Sell | 1,013 | $9.05 | $9,167.65 | 26,274 | |
| 8/1/2016 | Robert A Copeland | Insider | Sell | 4,000 | $10.37 | $41,480.00 | 35,538 | |
| 7/11/2016 | Andrew E Singer | CFO | Sell | 1,013 | $10.36 | $10,494.68 | 24,828 | |
| 7/5/2016 | Robert A Copeland | Insider | Sell | 4,000 | $10.03 | $40,120.00 | 4,000 | |
| 6/9/2016 | Andrew E Singer | CFO | Sell | 1,013 | $12.49 | $12,652.37 | 23,382 | |
| 4/12/2016 | Andrew E Singer | CFO | Sell | 1,013 | $12.42 | $12,581.46 | 20,489 | |
| 3/9/2016 | Andrew E Singer | CFO | Sell | 1,006 | $9.33 | $9,385.98 | 19,036 | |
| 2/29/2016 | Peter Tai-Ching Ho | Insider | Buy | 636 | $7.47 | $4,750.92 | | |
| 2/10/2016 | Andrew E. Singer | CFO | Sell | 12,158 | $9.54 | $115,987.32 | 17,354 | |
| 1/12/2016 | Bay City Capital Fund V Co-Inv | Major Shareholder | Buy | 555,555 | $9.00 | $4,999,995.00 | | |
| 1/12/2016 | David M Mott | Director | Buy | 1,111,111 | $9.00 | $9,999,999.00 | | |
| 1/4/2016 | Robert A. Copeland | insider | Sell | 4,185 | $15.58 | $65,202.30 | | |
| 12/30/2015 | Robert J. Gould | Director | Sell | 32,108 | $18.01 | $578,265.08 | | |
| 12/9/2015 | Peter Tai-Ching Ho | Insider | Buy | 1,000 | $14.69 | $14,690.00 | | |
| 12/7/2015 | Robert A. Copeland | insider | Sell | 4,185 | $13.82 | $57,836.70 | | |
| 11/9/2015 | Robert A. Copeland | insider | Sell | 4,185 | $16.26 | $68,048.10 | | |
| 10/5/2015 | Robert A. Copeland | insider | Sell | 4,185 | $14.43 | $60,389.55 | | |
| 9/8/2015 | Robert A. Copeland | insider | Sell | 4,185 | $19.58 | $81,942.30 | | |
| 9/8/2015 | Robert J. Gould | CEO | Sell | 60,000 | $19.86 | $1,191,600.00 | | |
| 7/6/2015 | Robert A Copeland | Insider | Sell | 8,371 | $22.86 | $191,361.06 | | |
| 7/6/2015 | Robert J Gould | CEO | Sell | 60,000 | $23.22 | $1,393,200.00 | | |
| 5/5/2015 | Peter Tai-Ching Ho | Insider | Buy | 800 | $16.36 | $13,088.00 | | |
| 12/2/2014 | Peter Tai-Ching Ho | Insider | Buy | 1,000 | $21.17 | $21,170.00 | | |
| 11/17/2014 | Robert A Copeland | EVP | Sell | 20,000 | $22.68 | $453,600.00 | | |
| 11/3/2014 | Robert A Copeland | EVP | Sell | 20,000 | $25.47 | $509,400.00 | | |
| 11/3/2014 | Robert J Gould | CEO | Sell | 30,000 | $24.95 | $748,500.00 | | |
| 10/7/2014 | Robert A Copeland | EVP | Sell | 20,000 | $26.90 | $538,000.00 | | |
| 10/1/2014 | Robert J Gould | CEO | Sell | 30,000 | $26.28 | $788,400.00 | | |
| 10/1/2014 | Stephen Garbacz | Insider | Sell | 868 | $27.06 | $23,488.08 | | |
| 9/22/2014 | Robert A Copeland | EVP | Sell | 20,000 | $25.55 | $511,000.00 | | |
| 9/15/2014 | Eric Hedrick | Insider | Sell | 2,000 | $28.67 | $57,340.00 | | |
| 9/4/2014 | Carl Goldfischer | Director | Sell | 4,000 | $35.14 | $140,560.00 | | |
| 8/26/2014 | Bay City Capital Llc | Major Shareholder | Sell | 200,000 | $35.14 | $7,028,000.00 | | |
| 8/25/2014 | Bay City Capital Llc | Major Shareholder | Sell | 366,666 | $33.98 | $12,459,310.68 | | |
| 8/18/2014 | Robert A Copeland | EVP | Sell | 10,830 | $36.07 | $390,638.10 | | |
| 8/15/2014 | Ryan D Drant | Major Shareholder | Sell | 4,061 | $36.54 | $148,388.94 | | |
| 8/4/2014 | Jason P Rhodes | CFO | Sell | 30,000 | $29.74 | $892,200.00 | | |
| 8/4/2014 | Robert A Copeland | EVP | Sell | 20,000 | $29.42 | $588,400.00 | | |
| 7/15/2014 | Eric Hedrick | Insider | Sell | 2,000 | $31.35 | $62,700.00 | | |
| 7/7/2014 | Jason P Rhodes | CFO | Sell | 30,000 | $32.74 | $982,200.00 | | |
| 7/1/2014 | Robert J Gould | CEO | Sell | 30,000 | $31.53 | $945,900.00 | | |
| 6/23/2014 | Robert A Copeland | EVP | Sell | 20,000 | $28.42 | $568,400.00 | | |
| 6/16/2014 | Eric Hedrick | Insider | Sell | 2,000 | $26.42 | $52,840.00 | | |
| 6/16/2014 | Robert A Copeland | EVP | Sell | 25,012 | $26.38 | $659,816.56 | | |
| 6/2/2014 | Robert J Gould | CEO | Sell | 30,000 | $22.20 | $666,000.00 | | |
| 5/19/2014 | Robert Copeland | EVP | Sell | 5,000 | $22.28 | $111,400.00 | 17,561 | |
| 5/5/2014 | Jason Rhodes | CFO | Sell | 30,000 | $21.53 | $645,900.00 | 46,000 | |
| 5/5/2014 | Robert Copeland | EVP | Sell | 10,000 | $21.29 | $212,900.00 | 20,011 | |
| 5/1/2014 | Robert Gould | CEO | Sell | 30,000 | $21.91 | $657,300.00 | | |
| 4/28/2014 | Robert Copeland | EVP | Sell | 13,800 | $20.73 | $286,074.00 | 24,911 | |
| 4/7/2014 | Jason Rhodes | CFO | Sell | 25,000 | $20.05 | $501,250.00 | 34,000 | |
| 4/7/2014 | Robert Gould | CEO | Sell | 30,000 | $20.22 | $606,600.00 | | |
| 2/10/2014 | Celgene European Investment Co | major shareholder | Buy | 340,000 | $29.25 | $9,945,000.00 | | |
| 1/6/2014 | Jason Rhodes | CFO | Sell | 10,000 | $20.19 | $201,900.00 | 4,000 | |
| 12/16/2013 | Robert Copeland | EVP | Sell | 4,600 | $21.21 | $97,566.00 | 53,544 | |
| 12/2/2013 | Robert Copeland | EVP | Sell | 5,000 | $20.70 | $103,500.00 | 53,544 | |
| 11/15/2013 | M James Barrett | major shareholder | Buy | 406,500 | $19.68 | $7,999,920.00 | | |
| 6/5/2013 | David M Mott | Director | Buy | 400,000 | $15.00 | $6,000,000.00 | | |
| 6/5/2013 | Venture Fund I L.P. Astellas | Major Shareholder | Buy | 15,333 | $15.00 | $229,995.00 | | |
(Data available from 1/1/2013 forward)
Epizyme (NASDAQ EPZM) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Epizyme (EPZM) PT Set at $24.00 by Roth Capital
www.americanbankingnews.com - April 25 at 10:30 AM |
| Epizyme (EPZM) Rating Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - April 25 at 12:58 AM |
| BidaskClub Lowers Epizyme (EPZM) to Hold
www.americanbankingnews.com - April 25 at 12:26 AM |
 | 'We Expect A Quick Resolution': Despite Partial Clinical Hold On Epizyme's Drug Candidate, Wedbush Stays Bullish
finance.yahoo.com - April 24 at 5:13 PM |
 | Epizyme Shares Drop After Partial Clinical Hold Placed On Lead Cancer Drug
feeds.benzinga.com - April 24 at 10:49 AM |
| Leerink Swann Analysts Give Epizyme (EPZM) a $24.00 Price Target
www.americanbankingnews.com - April 24 at 9:30 AM |
| Wedbush Lowers Epizyme (EPZM) Price Target to $20.00
www.americanbankingnews.com - April 24 at 9:12 AM |
| SunTrust Banks Reiterates Buy Rating for Epizyme (EPZM)
www.americanbankingnews.com - April 24 at 8:54 AM |
 | PRTA Jolted, FDA Strikes Down PFE's Herceptin Biosimilar, No Relief Yet For KMDA
www.nasdaq.com - April 24 at 8:45 AM |
| US STOCKS ON THE MOVE-Incyte, Epizyme, Shire, Valeritas
www.nasdaq.com - April 24 at 8:45 AM |
 | Biotech Analysis Central Pharma News: Orexigen's Last Resort, Epizyme's Partial Clinical Hold, Eli Lilly And Incyte's ...
seekingalpha.com - April 24 at 8:45 AM |
| $750,000.00 in Sales Expected for Epizyme (EPZM) This Quarter
www.americanbankingnews.com - April 24 at 4:48 AM |
 | Epizyme (EPZM) Says US-based Enrollment of New Patients into Tazemetostat Clinical Trials is Temporarily on Hold
www.streetinsider.com - April 23 at 4:54 PM |
| Epizyme Provides Update Regarding Tazemetostat Clinical Program
finance.yahoo.com - April 23 at 4:54 PM |
| -$0.54 Earnings Per Share Expected for Epizyme (EPZM) This Quarter
www.americanbankingnews.com - April 22 at 3:08 AM |
 | Why Is Epizyme (EPZM) Down 18% Since Its Last Earnings Report?
www.zacks.com - April 12 at 9:26 AM |
| Epizyme's (EPZM) "Buy" Rating Reiterated at HC Wainwright
www.americanbankingnews.com - April 12 at 12:29 AM |
| Epizyme (EPZM) Publishes Tazemetostat Phase I Data, Stock Up
finance.yahoo.com - April 11 at 5:03 PM |
| Epizyme (EPZM) Reports Publication of Tazemetostat Phase 1 Clinical Data in The Lancet Oncology
www.streetinsider.com - April 10 at 5:05 PM |
| Epizyme (EPZM) Downgraded to "Hold" at BidaskClub
www.americanbankingnews.com - April 10 at 10:25 AM |
| ValuEngine Downgrades Epizyme (EPZM) to Strong Sell
www.americanbankingnews.com - April 10 at 12:32 AM |
| Epizyme (EPZM) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - April 7 at 9:13 AM |
| Epizyme (EPZM) Expected to Announce Quarterly Sales of $750,000.00
www.americanbankingnews.com - April 7 at 4:43 AM |
 | BRIEF-Epizyme Inc Files For Potential Mixed Shelf, Size Not Disclosed
www.reuters.com - April 6 at 9:00 AM |
| Zacks: Analysts Anticipate Epizyme (EPZM) Will Post Earnings of -$0.54 Per Share
www.americanbankingnews.com - April 5 at 5:28 AM |
| Epizyme (EPZM) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - April 5 at 3:24 AM |
| Epizyme (EPZM) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 3 at 11:02 AM |
| Epizyme (EPZM) Rating Lowered to Sector Perform at Royal Bank of Canada
www.americanbankingnews.com - April 2 at 8:40 AM |
| Epizyme (EPZM) Given Buy Rating at Cann
www.americanbankingnews.com - April 2 at 8:31 AM |
| Epizyme (EPZM) Rating Reiterated by HC Wainwright
www.americanbankingnews.com - April 1 at 11:24 PM |
| Epizyme (EPZM) Rating Lowered to Sell at ValuEngine
www.americanbankingnews.com - April 1 at 7:35 PM |
| Edited Transcript of EPZM earnings conference call or presentation 13-Mar-18 12:30pm GMT
finance.yahoo.com - April 1 at 8:49 AM |
| Zacks Investment Research Lowers Epizyme (EPZM) to Sell
www.americanbankingnews.com - March 30 at 10:02 PM |
| Epizyme (EPZM) Earns Overweight Rating from Analysts at Morgan Stanley
www.americanbankingnews.com - March 29 at 3:01 PM |
| Epizyme (EPZM) Upgraded at BidaskClub
www.americanbankingnews.com - March 24 at 10:59 AM |
| Epizyme Inc (EPZM) Expected to Post Earnings of -$0.54 Per Share
www.americanbankingnews.com - March 19 at 3:06 AM |
| Wedbush Weighs in on Epizyme Inc's Q1 2018 Earnings (EPZM)
www.americanbankingnews.com - March 19 at 1:54 AM |
| Epizyme (EPZM) Rating Increased to Buy at BidaskClub
www.americanbankingnews.com - March 17 at 6:14 PM |
| Epizyme (EPZM) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - March 16 at 12:04 PM |
| Epizyme Inc Forecasted to Earn Q2 2018 Earnings of ($0.59) Per Share (EPZM)
www.americanbankingnews.com - March 16 at 9:06 AM |
| Epizyme (EPZM) Reports Narrower-than-Expected Loss in Q4 - Nasdaq
www.nasdaq.com - March 16 at 8:54 AM |
| Oppenheimer Weighs in on Epizyme Inc's Q1 2018 Earnings (EPZM)
www.americanbankingnews.com - March 16 at 8:40 AM |
| Epizyme Inc to Post Q1 2018 Earnings of ($0.54) Per Share, Leerink Swann Forecasts (EPZM)
www.americanbankingnews.com - March 16 at 8:37 AM |
| FY2022 EPS Estimates for Epizyme Inc Reduced by Analyst (EPZM)
www.americanbankingnews.com - March 15 at 3:10 PM |
| Epizyme (EPZM) Upgraded at Zacks Investment Research
www.americanbankingnews.com - March 15 at 12:51 PM |
| FY2018 EPS Estimates for Epizyme Inc Decreased by Analyst (EPZM)
www.americanbankingnews.com - March 15 at 9:28 AM |
| Epizyme (EPZM) Given New $24.00 Price Target at Leerink Swann
www.americanbankingnews.com - March 14 at 9:02 PM |
| Wedbush Lowers Epizyme (EPZM) Price Target to $25.00
www.americanbankingnews.com - March 14 at 9:02 PM |
| Epizyme (EPZM) Rating Reiterated by SunTrust Banks
www.americanbankingnews.com - March 14 at 9:02 PM |
 | Epizyme (EPZM) Reports Narrower-than-Expected Loss in Q4
www.msn.com - March 14 at 6:31 PM |
Epizyme (NASDAQ:EPZM) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Epizyme (NASDAQ:EPZM) Income Statement, Balance Sheet and Cash Flow Statement
Epizyme (NASDAQ EPZM) Stock Chart for Wednesday, April, 25, 2018
Loading chart…
